Compare Inovio Pharmaceuticals Inc (INO) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $112.19M), while YieldMax MSTR Option Income Strategy ETF trades at $15.42 (market cap $1.06B). The key difference: YieldMax MSTR Option Income Strategy ETF is far larger — about 9.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and YieldMax MSTR Option Income Strategy ETF for 30 Days on average.
| INO | MSTY | |
|---|---|---|
Market Cap | $112.19M | $1.06B |
Volume | 3,201,278 | 2,402,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $2.65 | $67.85 |
52-Week Low | $0.66 | $11.55 |
Typical Hold Time | 43 Days | 30 Days |
Enterprise Value | $83.51M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
MSTY trades at $15.83, down 5.61% today amid bearish technical signals. The ETF shows mixed sentiment with Seeking Alpha rating it Hold despite a 100.32% annualized distribution rate. Recent articles highlight significant NAV erosion, with $10,000 investments declining to approximately $6,614 over six months according to 24/7 Wall Street analysis from July 2026.
The fund's high distribution strategy comes with substantial principal erosion risk. While weekly dividends provide income, the structural design returns investor capital as distributions. Analyst consensus remains cautious due to the fund's dependence on MSTR volatility and ongoing NAV decline, making this suitable only for sophisticated investors understanding the income-principal tradeoff.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
